project . 2020 - 2025 . On going

MOLEC ANTI-ARRHYT

Resilience and Trigger Factors in Cardiac Arrhythmia: Risk Stratification and Drug Design
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 850622 Call for proposal: ERC-2019-STG
  • Funded under: H2020 | ERC | ERC-STG Overall Budget: 1,500,000 EURFunder Contribution: 1,500,000 EUR
  • Status: On going
  • Start Date
    01 Mar 2020
    End Date
    28 Feb 2025
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Up to 30% of individuals with inherited cardiac arrhythmias such as Long QT syndrome are not protected from sudden cardiac death despite state-of-the-art treatment. A major hurdle for effective risk stratification and treatment of inherited cardiac arrhythmias is the poor correlation between genetic variant and clinical manifestations. Affected individuals, who harbour the same arrhythmia-causative mutation, paradoxically display a spectrum of clinical phenotypes ranging from a lifelong asymptomatic state to sudden death in infancy. Up to 40% of genotype-positive individuals, depending on type of arrhythmia, do not display clinical manifestation. Based on our un...
Partners
Description
Up to 30% of individuals with inherited cardiac arrhythmias such as Long QT syndrome are not protected from sudden cardiac death despite state-of-the-art treatment. A major hurdle for effective risk stratification and treatment of inherited cardiac arrhythmias is the poor correlation between genetic variant and clinical manifestations. Affected individuals, who harbour the same arrhythmia-causative mutation, paradoxically display a spectrum of clinical phenotypes ranging from a lifelong asymptomatic state to sudden death in infancy. Up to 40% of genotype-positive individuals, depending on type of arrhythmia, do not display clinical manifestation. Based on our un...
Partners
Any information missing or wrong?Report an Issue